Abstract-The inhibitory effect of sulpiride on dopamine receptors was investigated in the exocrine pancreas of dogs anesthetized with pentobarbital and with the stomach ligated at the pylorus. All test substances were given intravenously. Dopamine, acetylcholine, histamine and secretin produced a dose-related increase in pancreatic juice secretion, though the dose-effect curves of these secretagogues differed in shape. Epinephrine, norepinephrine, isoproterenol, methamphetamine and serotonin had no secretagogue effects. The effects of acetylcholine and histamine were inhibited by atropine and cimetidine, respectively. The effect of dopamine was blocked by halo peridol, but not by atropine, cimetidine, phentolamine and propranolol. These results suggest that dopamine acts on specific dopamine receptors related to the exocrine pancreatic secretion.
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Haloperidol had no effect on the effects of acetylcholine and histamine, but did inhibit the secretin-induced secretion, though the inhibitory effect was to a lesser extent than on the dopamine response. Sulpiride and chlorpromazine also suppressed dose-dependently the dopamine-induced secretion. The inhibitory activity of sulpiride was almost the same as that of haloperidol, and 12 times more potent than that of chlorpromazine.
Sulpiride was found to be a potent dopamine antagonist in the canine exocrine pancreas.
In a previous report we showed that sulpiride`, an antipsychotic drug, has essentially a potent inhibition on dopamine receptors in the central nervous system. This drug, when given intraventricularly to rats, was equally or more effective than haloperidol in inducing catalepsy and in inhibiting apomorphine and methamphetamine-induced circling behavior (1) . The present paper deals with antagonism of sulpiride to dopamine in the exocrine pancreas of dogs.
Hashimoto and collaborators demonstrated that exogenous dopamine increases the secretion of pancreatic juice, of which the components are similar to those induced by exogenous secretin (2) , and that there are specific dopamine receptors related to the exocrine pancreatic secretion in dogs (3) (4) (5) (6) . Thus, the dopamine receptor response can be easily quantified by measuring the increases in volume of the pancreatic juice. This system is a convenient tool for studies on the interaction between dopamine and test substances.
We attempted to evaluate the antidoparnine activity of sulpiride, chlorpromazine and haloperidol given to anesthetized dogs before an i.v. administration of dopamine in order to evoke increased pancreatic secretion. We also examined the specificity of the pancreatic dopamine receptor response to dopamine injected systemically, as the dopamine receptor specificity was investigated by Hashimoto and colleagues in the isolated blood-perfused canine pancreas preparation (3-6).
MATERIALS AND METHODS
Animals: Adult mongrel dogs of either sex, weighing 8 to 23 kg, were anesthetized with pentobarbital-Na in a dose of 35 mg/kg (i.p.). Operation and general procedure: The abdomen was opened along the midline and the ventral pancreatic duct was carefully separated from the connective tissues close to the duodenum. After a longitudinal incision of the duodenal wall, a polyethylelne tube was inserted from the opening into the ventral duct through the papilla and was secured in place.
To avoid the possible influence of the gastric juice on the pancreatic secretion, the stomach was ligated at the pylorus. All test drugs were given i.v. through a catheter placed in the femoral vein.
Secretagogue effect: After an injection of a test substance, the increased number of drops was counted at 5 min intervals until the secretory rate returned to the basal level.
The results were averaged for each dose group.
Effect of blockers on secretagogue-induced secretion: The secretagogue, dopamine (16 ,ng/kg), secretin (100 mU/kg), acetylcholine (64 t.tg/kg) and histamine (16 ag/kg) were used at the fixed dose shown in the parentheses. 
RESULTS
Effects of secrctagognes on pancreatic secretion: Response of the dog exocrine pancreas to secretagogue given i.v. are summarized in Table 1 .
Dopamine increased the pancreatic secretion dose dependently in doses of I to 1000 /rg/ kg. A typical recording is shown in Fig. 1 . Histamine was effective in stimulating the pancreatic secretion in doses of 4 to 64 ,eg/ kg. Howescr, 250 ;pg/kg of histamine did not further increase the secretion, and 2/4 animals died within 20 min after the injection. The effect of histamine in doses of 4 to 64 ,,ig/kg was about half that of corresponding doses of dopamine.
Acetylcholine also increased the secretion in doses of 1 to 1000 ;gig/kg, but the effect was to a lesser extent than that of dopamine, and leveled off with doses of 64 to 1000 g kg. Secretin produced an increase in the pancreatic secretion in doses up to 1000 mU/kg.
The action of all tested secretagogues was rapid in onset, reached a maximum within one minute and disappeared rapidly. Thus, the total increase in the pancreatic secretion Epinephrine, norepinephrine, isoproterenol, serotonin at a dose of 64 /€g/kg, and methamphetamine at a dose of 4000 /ig/kg had no effect on the pancreatic secretion (data not shown).
Effects of blockers on sccretagogue-induced secretion: To ascertain the specificity of secretagogue-induced pancreatic secretion, effects of typical blockers were investigated.
Dopamine-induced secretion: Haloperidol inhibited the dopamine-induced secretion dose dependently in doses of 0.064 to 4 mg/kg ( Table 2 ). The maximum effect was noted 1 min after the injection (Fig. 3A) . A 50 % inhibition was achieved with a dose of less than 1 mg/kg. The dopamine-induced secretion was not attenuated by atropine, cimetidine, phentolamine and propranolol. Histamine-induced secretion: Cimetidine inhibited the histamine-induced secretion dose dependently in doses of 0.064 to 1 mg/kg, while diphenhydramine was ineffective up to 4 mg/kg ( Table 3 ). The maximum effect of cimetidine was noted I min after the injection (Fig. 3B ). Atropine and haloperidol inhibited only slightly the histamine-induced secretion, at a dose as high as 1 mg/kg.
Acetylcholine-induced secretion: Atropine inhibited the acetylcholine-induced secretion, dose dependently, in doses of 0.016 to 1 mg/kg ( Table 4 ). The maximum effect of atropine was at 1 min after the injection (Fig. 3C ). An almost complete inhibition was noted with a dose as low as 0.064 mg/kg of atropine.
Cimetidine and haloperidol did not significantly inhibit the acetylcholine-induced secretion in a dose of 1 mg/kg. dently the secretin-induced secretion (Table 5) . However, the effect was less than on the dopamine-induced secretion, in corresponding doses. A dose of 4 mg/kg of haloperidol was required to achieve about 50% inhibition. Atropine and cimetidine did not affect the secretin-induced secretion in a dose of 1 mg/kg. Effect of neuroleptics on dopamine-induced secretion: Pretreatment of dogs with sulpiride and chlorpromazine produced an inhibition of the dopamine-induced pancreatic secretion (Fig. 4), as did haloperidol (Fig. 3A) . There were no considerable differences in the duration of the inhibitory effect among these neuroleptics. The dose-effect curve for each neuroleptic drug was prepared from the maximum effect in each dose of the drug (Fig. 5) . According to the dose required to suppress the dopamine-induced secretion by 50% (ED50), sulpiride was almost equipotent to haloperidol and about 12 times more potent than chlorpomazine.
DISCUSSION
Physiologically, the pancreatic secretion is primarily controlled by secretin and cholesy stokinin (7, 8) . The involvement of cholinergic function in the pancreatic secretion has also been described (9) (10) (11) (12) . Furthermore, systemically administered histamine (12) and dopamine (2) enhance the secretory rate.
In the present study, acetylcholine, histamine, dopamine and secretin dose-dependently increased the rate of the pancreatic secretion. The dose effect curves for these secretagogues differed in shape suggesting that these secretagogues acted through different mechanisms.
Since the stomach was ligated at the pylorus, the effects of acetylcholine and histamine cannot be ascribed to their stimulant action on the gastric secretion, which may lead to acidification of the duodenal lumen and eventually evoke the endogenous secretin mechanism.
The acetylcholine-induced secretion was strongly inhibited by atropine, as reported by Hickson (11) . The histamine-induced secretion was effectively suppressed by cimetidine, a histamine H2-receptor blocker, but not by diphenhydramine, a histamine H,-receptor blocker.
The effect of cimetidine was specific for the histamine-induced secretion, because the blocker did not inhibit the effect of any other secretagogues. This finding suggests that the histamine receptors in the exocrine pancreas of dog are of H2-sub-type, similar to those related to the gastric secretion in the stomach (13) . Alternatively, the histamine-induced secretion might have resulted from the increase in the peripheral blood flow which was mediated by stimulation of the cimetidine sensitive vascular H2-receptors (14, 15) . However, the possibility is unlikely, because strong peripheral vasodilators, which increase the pan creatic blood flow as does histamine, do not always enhance the pancreatic secretion (5).
Thus, histamine is assumed to have acted directly on the pancreatic exocrine system. The dopamine-induced secretion was attenuated by haloperidol, a typical dopamine receptor blocker, as already reported by Furuta et al. (4) . On the other hand, the effect of dopamine was not influenced by atropine, cimetidine, phentolamine and propranolol. Furthermore, epinephrine, norepinephrine, isoproterenol and serotonin did not increase the secretion.
These findings show that dopamine evoked pancreatic secretion through direct stimulation of specific dopamine receptors, without implication of receptors responding to acetylcholine, histamine, norepinephrine, epinephrine or serotonin.
Sulpiride dose-dependently attenuated the dopamine-induced secretion. The inhibitory activity of stilpiride was almost the same as that of haloperidol, and about 12 times more potent than that of chlorpromazine. The relative potencies among sulpiride, haloperidol and chlorpromazine were similar to those in the central nervous system, as observed in behavioral experiments in rats in which the test drugs were administered intraventricularly (1). Furthermore, Goldberg (16) reported that sulpiride inhibited the canine renal vascular response to dopamine more strongly than did haloperidol and chlorpromazine. These findings show that sulpiride is a potent dopamine antagonist also in the peripheral organs.
The anti-dopamine character of sulpiride in the central nervous system has been described in many reports (1, (17) (18) (19) (20) (21) (22) (23) . However, the drug was reported not to block the dopamine-sensitive adenylate cyclase (24, 25) . In this respect, the dopamine receptors in the exocrine pancreas could be postulated to have a property pharmacologically in common with that of a subgroup of central dopamine receptors not associated with adenylate cyclase.
The physiological role of the pancreatic dopamine receptors has not been elucidated, while dopamine is known to be present in the canine pancreas in a concentration of about 140 ng/g wet weight of tissue (6) . The endogenous pool of dopamine cannot be assumed to be associated with neural structures, since 1) methamphetamine, which exerts its dopaminergic effects through the release of dopamine from the dopaminergic neurons, such as is the case with amphetamine (26-28), did not trigger pancreatic secretion in the present study, and 2)
Furuta et al. (6) reported that reserpine did not reduce endogenous dopamine concentration in the canine pancreas, in the dose which reduced norepinephrine content by 96%.
With respect to the relationship between secretin and dopamine, Furuta et al. (6) re ported that apomorphine inhibited the effect of dopamine while it did not alter the effect of secretin, and Iwatsuki et al. (29) showed that prostaglandin F2a inhibited the effect of secretin but not dopamine. These findings could exclude the possibility that a common mechanism is involved in the enhancement of pancreatic secretion by secretin and dopamine. However, in the present study, haloperidol significantly inhibited the effect of secretin, although the effect seemed to be less potent than that on the dopamine-induced secretion.
The effect of haloperidol must be specific because the drug did not affect the secretagogue action of acetylcholine or histamine. These findings suggest that secretin function was mediated at least partially by endogenous dopamine. More detailed studies are required to elucidate the physiological relationship between secretin and dopamine in the exocrine pancreas.
